Nanoparticle therapy that activates immune response against tumors
Tumor-activatable Interleukin-2 Superkine Nanoparticle Therapy
['FUNDING_R01'] · UT SOUTHWESTERN MEDICAL CENTER · NIH-11036389
This study is testing a new cancer treatment that uses tiny particles to deliver a special version of a protein that helps your immune system fight tumors, aiming to make the treatment safer and more effective for people with certain types of cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UT SOUTHWESTERN MEDICAL CENTER (nih funded) |
| Locations | 1 site (DALLAS, UNITED STATES) |
| Trial ID | NIH-11036389 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new type of cancer treatment that uses engineered nanoparticles to deliver a modified version of interleukin-2 (IL-2), a protein that helps activate the immune system to fight tumors. The approach aims to minimize side effects commonly associated with traditional IL-2 therapies by ensuring that the treatment specifically targets cancer cells in acidic tumor environments. By enhancing the effectiveness of immune cells like CD8+ T cells and natural killer cells, this therapy seeks to improve outcomes for patients with certain types of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that are responsive to IL-2 therapy, such as renal and skin cancers.
Not a fit: Patients with cancers that do not respond to IL-2 or those with significant immune system dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer immunotherapy option for cancer patients.
How similar studies have performed: Previous research has shown promise in using engineered IL-2 therapies, but this specific approach combining nanoparticles with IL-2 muteins is relatively novel.
Where this research is happening
DALLAS, UNITED STATES
- UT SOUTHWESTERN MEDICAL CENTER — DALLAS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GAO, JINMING — UT SOUTHWESTERN MEDICAL CENTER
- Study coordinator: GAO, JINMING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy